Royalty Pharma plc

NasdaqGS:RPRX Stock Report

Market Cap: US$25.8b

Royalty Pharma Future Growth

Future criteria checks 3/6

Royalty Pharma is forecast to grow earnings and revenue by 4% and 10.8% per annum respectively. EPS is expected to grow by 6.5% per annum. Return on equity is forecast to be 24.6% in 3 years.

Key information

4.0%

Earnings growth rate

6.45%

EPS growth rate

Pharmaceuticals earnings growth11.3%
Revenue growth rate10.8%
Future return on equity24.57%
Analyst coverage

Good

Last updated09 Feb 2026

Recent future growth updates

Recent updates

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated

Nov 15

Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price

Jul 06
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price

Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching

May 31
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching

Royalty Pharma: Delivering Growth With A Positive Story Ahead

Feb 13

Royalty Pharma: Key Strategic Updates To Be Priced In

Jan 15

Royalty Pharma: Massive Opportunity Ahead

Nov 09

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Aug 22

Royalty Pharma: Busy Putting Capital To Work

Aug 11

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Earnings and Revenue Growth Forecasts

NasdaqGS:RPRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20284,0781,0013,4183,7361
12/31/20273,5841,8313,2773,2386
12/31/20263,3331,5663,0693,0526
12/31/20253,2171,3522,7702,8096
9/30/20252,3507659452,405N/A
6/30/20252,3051,0217132,406N/A
3/31/20252,2641,0932802,700N/A
12/31/20242,2648592632,769N/A
9/30/20242,2661,145-2122,799N/A
6/30/20242,2386734012,669N/A
3/31/20242,2397991,0192,619N/A
12/31/20232,3551,1358722,988N/A
9/30/20232,3241841,4222,785N/A
6/30/20232,3612555222,750N/A
3/31/20232,3593323742,718N/A
12/31/20222,237434022,144N/A
9/30/20222,2475074012,064N/A
6/30/20222,2594663121,995N/A
3/31/20222,2786022631,952N/A
12/31/20212,289620-1742,018N/A
9/30/20212,286783-7322,093N/A
6/30/20212,239972-1592,132N/A
3/31/20212,195493-4962,090N/A
12/31/20202,122495-1482,035N/A
9/30/20202,0081,7451041,947N/A
6/30/20201,9341,8637931,858N/A
3/31/20201,8802,0521,0931,705N/A
12/31/20191,8142,349-541,667N/A
12/31/20181,7951,378N/A1,618N/A
12/31/20171,5981,210N/A1,418N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RPRX's forecast earnings growth (4% per year) is above the savings rate (3.4%).

Earnings vs Market: RPRX's earnings (4% per year) are forecast to grow slower than the US market (15.7% per year).

High Growth Earnings: RPRX's earnings are forecast to grow, but not significantly.

Revenue vs Market: RPRX's revenue (10.8% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: RPRX's revenue (10.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RPRX's Return on Equity is forecast to be high in 3 years time (24.6%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/09 12:21
End of Day Share Price 2026/02/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Royalty Pharma plc is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc
Prem ChulakiCrispIdea